Dashboard
Manage Tickers

AMGNAMGEN INC

Nasdaq amgen.com


$ 298.67 $ 0.12 (0.04 %)    

Friday, 14-Jun-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 298.62
$ 297.42
$ 0.00 x 0
$ 0.00 x 0
$ 295.95 - $ 299.58
$ 211.82 - $ 324.86
1,713,616
na
160.06B
$ 0.53
$ 42.54
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-09-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-09-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-13-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 04-25-2018 03-31-2018 10-Q
26 02-13-2018 12-31-2017 10-K
27 10-26-2017 09-30-2017 10-Q
28 07-26-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-14-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 05-02-2016 03-31-2016 10-Q
34 02-16-2016 12-31-2015 10-K
35 11-02-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 04-27-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amgen-announces-fda-approval-of-blincyto-in-cd19-positive-philadelphia-chromosome-negative-b-all
Amgen Announces FDA Approval Of BLINCYTO I...
06/14/2024 20:22:51

expert-ratings-for-amgen
Expert Ratings For Amgen
06/14/2024 17:00:24

rbc-capital-maintains-outperform-on-amgen-raises-price-target-to-332
RBC Capital Maintains Outperform on Amgen,...
06/14/2024 13:34:10

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $328 to $...

decoding-amgens-options-activity-whats-the-big-picture
Decoding Amgen's Options Activity: What's ...
06/12/2024 20:02:22

market-whales-and-their-recent-bets-on-amgn-options
Market Whales and Their Recent Bets on AMG...
06/06/2024 17:46:31

amgen-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-at-920-am-et-on-june-10
Amgen To Present At Goldman Sachs 45th Ann...
06/05/2024 20:01:09

amgen-seeks-expanded-us-approval-for-autoimmune-disease-drug-acquired-via-28b-horizon-deal
Amgen Seeks Expanded US Approval For Autoi...
06/05/2024 19:26:54

Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key s...

amgen-announces-phase-3-trial-results-for-uplizna-showing-87-reduction-in-igg4-rd-flares-first-randomized-placebo-controlled-trial-to-demonstrate-benefit-in-igg4-rd-all-primary-and-key-secondary-endpoints-met
Amgen Announces Phase 3 Trial Results For ...
06/05/2024 13:01:23

heres-how-much-you-would-have-made-owning-amgen-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
05/31/2024 18:00:45

amgen-secures-fda-nod-for-rare-disease-treatment-biosimilar-based-on-astrazenecas-drug
Amgen Secures FDA Nod For Rare-Disease Tre...
05/29/2024 16:51:29

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare d...

whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday
What's Going On With Mid-Cap Cancer-Focuse...
05/24/2024 12:45:21

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in ...

exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-ozempic
EXCLUSIVE: Roundhill Investments Launches ...
05/21/2024 20:33:05

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and c...

if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-5700-today
If You Invested $1000 In This Stock 20 Yea...
05/21/2024 15:00:42

Core News & Articles
Alvotech And Dr. Reddy's Enter Collaborato...
05/21/2024 12:05:27

amgenastrazeneca-say-asthma-drug-shows-activity-in-another-lung-disease-across-broad-patient-population
Amgen/AstraZeneca Say Asthma Drug Shows Ac...
05/20/2024 18:38:41

Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notab...

Core News & Articles
Reported Sunday, AstraZeneca And Amgen's T...
05/20/2024 04:55:49

Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE's impact on COPD exacerbations in patie...

cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch
Cannabis Meets Prescription Drugs, Steroid...
05/18/2024 14:19:14

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...

amgen-unusual-options-activity
Amgen Unusual Options Activity
05/17/2024 19:16:13

fda-gives-accelerated-approval-to-amgens-drug-for-small-cell-lung-cancer-patients
FDA Gives Accelerated Approval To Amgen's ...
05/17/2024 14:01:55

FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depen...

reported-earlier-fda-approves-amgens-imdelltra-tarlatamab-dlle-the-first-and-only-t-cell-engager-therapy-for-the-treatment-of-extensive-stage-small-cell-lung-cancer
Reported Earlier, FDA Approves Amgen's IMD...
05/17/2024 06:11:56

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response R...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)